Inotropic therapy for heart failure: an evidence-based approach.
about
The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivoThe perils of surrogate endpointsCardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal modelThe effect of milrinone on the intraoperative hemodynamics during off-pump coronary bypass surgery in patients with an elevated echocardiographic index of the ventricular filling pressureHemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?The relationship between systolic blood pressure on admission and mortality in older patients with heart failure.Role of RyR2 phosphorylation in heart failure and arrhythmias: protein kinase A-mediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmiasChronic inotropic therapy in end-stage heart failure.Effects of mild hypothermia on hemodynamics in cardiac arrest survivors and isolated failing human myocardium.Role of inotropic agents in the treatment of heart failure.Intravenous milrinone infusion improves congestive heart failure caused by diastolic dysfunction: a brief case seriesB-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure.Therapeutic options for the management of the cardiorenal syndrome.Nitroxyl gets to the heart of the matter.Acute decompensated heart failure is routinely treated as a cardiopulmonary syndromeNesiritide: a novel approach for acute heart failure.Long-term survival after mitral valve surgery for post-myocardial infarction papillary muscle ruptureHeart failure: a hemodynamic disorder complicated by maladaptive proliferative responses.Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry.Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model.New and emerging drug therapies for the management of acute heart failure.Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease.Cardiovascular manifestations of acute intracranial lesions: pathophysiology, manifestations, and treatment.Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure.Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction.Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failureLevosimendan, a new calcium-sensitizing inotrope for heart failure.Palliation of heart failure.An emerging role for calcium sensitisation in the treatment of heart failure.Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.A mathematical model for active contraction in healthy and failing myocytes and left ventricles.Perioperative management of patients with poorly functioning ventricles in the setting of the functionally univentricular heart.Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).Mild metabolic acidosis impairs the β-adrenergic response in isolated human failing myocardium.The utility of levosimendan in the treatment of heart failure.Evaluation of the anti-ischemic effects of D-ribose during dobutamine stress echocardiography: a pilot study.Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approachesRationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.Can we do better than dobutamine?Regulation of myocardial SERCA2a expression in ventricular hypertrophy and heart failure.
P2860
Q24643958-EB209B40-E28F-44EB-9E6E-7E19CDFED3DAQ27025740-74A8E742-1F13-42BB-8D25-41D84DB37800Q28243737-682A2E14-60ED-4399-9049-D33E6DDF70DBQ30475838-B6E8C42F-4D59-4842-812E-B9A404762D90Q30724401-3F994844-7457-42ED-BBCE-D79D95AD5F7CQ33595656-C13C1736-6F3D-4183-A51F-E737946B4043Q33693920-13EF652C-048B-496F-A9F6-562010A6210CQ33735360-84BE6E09-BE3E-4FB1-8D60-C5392CA59944Q33807092-B41A5805-0B58-42AC-9BA2-B0A8D6EC66AFQ33816527-4F7841FF-24ED-4592-A20C-E7BA70262C53Q33873912-6252F951-482B-4B71-815B-D49C5A8CD417Q34297057-F4FFB03A-5DAF-4904-A81F-DC8A077B72D9Q34442587-9A4EC857-D81F-4C4A-8590-52D745610F3AQ34981557-2E135A55-2B0C-444C-A3E4-66D4C8E77581Q35046502-1B27979A-90D8-4632-ACF2-10989D76E9FEQ35054263-4AD91A17-F4A8-4D6F-9B3A-8BDB50B12D7CQ35060428-F755B9A5-2586-4D13-BBE0-72912830F48AQ35136114-6778DF29-02B3-482D-ACE6-0D941666C89DQ35170235-CF7A23B7-A697-4EA7-8DCF-6EBB68ABC7CFQ35194984-E033A3B6-E056-4B17-979B-29931791ED40Q35600523-ACBCA1F2-3C58-4A1F-B163-844A90FC85A2Q35646696-9DD79045-869C-4C8F-AEFC-FC15FE311CC0Q35675955-890F5DA4-603F-4CBF-93B8-4CAA24496FCBQ35746978-424F3293-6CC2-4EF1-9C2A-E6430387D5D4Q35844522-AD1E5C03-98B9-44B0-B5D4-8AE84941DFE5Q35921523-A017D3EF-F339-425D-AB9B-5B112F435107Q35998009-742D5817-A104-48D6-8032-E536E6C3C7BDQ36135133-838E60CE-FB0E-42DE-AC28-2D1C50E6E23DQ36187050-B29309B0-E9EC-4A64-99A9-A846B98F4F96Q36284075-82971178-BD84-4628-9911-3392F6626903Q36346046-0C3AD9B9-4FA7-4FD5-9840-DD533260A472Q36364102-7B1FA844-9644-4F7B-88FF-CB2C210BA9D0Q36537384-543C02C3-A999-4475-B12B-61A99052F58FQ36634010-58BC5B8B-F50A-4AE9-B8FF-B12F7B762F53Q36761355-A63FCBD9-AD55-411C-994E-4170FCD358BBQ37102198-03C16EE5-35A1-4365-96B5-10D0EA2F2309Q37140940-9EDB1414-6900-4044-89AE-59C986171A4FQ37314355-CC358E6F-EA67-424F-8F84-F9C10C7BB112Q37406997-5F018F18-96FC-4AD5-9D19-82BEEC4772C7Q37608521-E63BD0A3-A9EE-4998-ACFA-F4D743A64321
P2860
Inotropic therapy for heart failure: an evidence-based approach.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inotropic therapy for heart failure: an evidence-based approach.
@ast
Inotropic therapy for heart failure: an evidence-based approach.
@en
Inotropic therapy for heart failure: an evidence-based approach.
@nl
type
label
Inotropic therapy for heart failure: an evidence-based approach.
@ast
Inotropic therapy for heart failure: an evidence-based approach.
@en
Inotropic therapy for heart failure: an evidence-based approach.
@nl
prefLabel
Inotropic therapy for heart failure: an evidence-based approach.
@ast
Inotropic therapy for heart failure: an evidence-based approach.
@en
Inotropic therapy for heart failure: an evidence-based approach.
@nl
P356
P1476
Inotropic therapy for heart failure: an evidence-based approach
@en
P2093
O'Connor CM
P304
P356
10.1067/MHJ.2001.117606
P407
P50
P577
2001-09-01T00:00:00Z